Trials / Completed
CompletedNCT02035553
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin tartrate | Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin) |
| DRUG | Placebo | Placebo, two tablets, once daily by mouth |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-09-28
- Completion
- 2016-10-27
- First posted
- 2014-01-14
- Last updated
- 2017-10-25
- Results posted
- 2017-10-25
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02035553. Inclusion in this directory is not an endorsement.